A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

Published:2012-05-29 Issue:1 Volume:12 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Hosein Peter J,Macintyre Jessica,Kawamura Carolina,Maldonado Jennifer Cudris,Ernani Vinicius,Loaiza-Bonilla Arturo,Narayanan Govindarajan,Ribeiro Afonso,Portelance Lorraine,Merchan Jaime R,Levi Joe U,Rocha-Lima Caio M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-12-199.pdf

Reference13 articles.

1. American Cancer Society: Cancer Facts & Figures 2011. 2011, American Cancer Society, Atlanta

2. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009, 16 (7): 1727-33. 10.1245/s10434-009-0408-6.

3. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010, 7 (4): e1000267-10.1371/journal.pmed.1000267.

4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M: Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364 (19): 1817-25. 10.1056/NEJMoa1011923.

5. Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ: A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer: A Hoosier Oncology Group Study. Am J Clin Oncol. 2011, 34 (5): 460-5. 10.1097/COC.0b013e3181e9c103.

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients with Pancreatic Ductal Adenocarcinoma;Annals of Surgery;2023-10-13

2. Pancreatic adenocarcinoma and aging: understanding the menace for better management;Journal of Pancreatology;2023-06-26

3. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival;Clinical Oncology;2023-05

4. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer;Surgery Open Science;2022-10

5. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population;Asia-Pacific Journal of Clinical Oncology;2022-07-13